Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma

BACKGROUND: Monoclonal antibodies targeting the cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) (e.g., ipilimumab [IPI]) and the programmed cell death-1 (PD1) receptor (e.g., nivolumab [NIVO]) represent significant breakthroughs in the treatment of advanced melanoma. A combination of the 2 agent...

Descripción completa

Detalles Bibliográficos
Autores principales: Potluri, Ravi, Ranjan, Sandip, Bhandari, Hitesh, Johnson, Helen, Moshyk, Andriy, Kotapati, Srividya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6610852/
https://www.ncbi.nlm.nih.gov/pubmed/31312536
http://dx.doi.org/10.1186/s40164-019-0138-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6610852/
https://www.ncbi.nlm.nih.gov/pubmed/31312536
http://dx.doi.org/10.1186/s40164-019-0138-9

Ejemplares similares